Impact of high-throughput screening in biomedical research
The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
Abstract
High-throughput screening (HTS) has been postulated in several quarters to be a contributory factor to the decline in productivity in the pharmaceutical industry. Moreover, it has been blamed for stifling the creativity that drug discovery demands. In this article, we aim to dispel these myths and present the case for the use of HTS as part of a proven scientific tool kit, the wider use of which is essential for the discovery of new chemotypes.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Cell-based phenotypic screening of chemical libraries represents a powerful tool to identify new potential drugs48.”
From Identification and characterization of Cardiac Glycosides as senolytic compounds (2019) · cites this paper as [48]
Citations
Cites
Zhang, J.-H., Chung, T. D. Y., & Oldenburg, K. R. (1999) · SLAS Discovery · doi:10.1177/108705719900400206 · Cited by 6,847 · cited 1×
“HTS laboratories have pioneered and implemented rigorous quality assurance methods, such as Z′ trend monitoring”
MethodCan the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3078 · Cited by 3,566 · cited 1×
“These efforts typically take 2–3 years in most drug discovery companie”
BackgroundDrug repositioning: identifying and developing new uses for existing drugs
Ashburn, T. T., & Thor, K. B. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1468 · Cited by 3,237 · cited 1×
“There have been numerous analyses of pharmaceutical industry productivity, and several of these have blamed high-throughput screening (HTS) as a factor undermining the creativity that has sustained the industry over the past centur”
BackgroundDiscovery and development of sorafenib: a multikinase inhibitor for treating cancer
Wilhelm, S., Carter, C., Lynch, M., Lowinger, T., Dumas, J., Smith, R. A., Schwartz, B., Simantov, R., & Kelley, S. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2130 · Cited by 1,829
Lessons from 60 years of pharmaceutical innovation
Munos, B. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2961 · Cited by 1,207
Dorr, P., Westby, M., Dobbs, S., Griffin, P., Irvine, B., Macartney, M., Mori, J., Rickett, G., Smith-Burchnell, C., Napier, C., et al. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.11.4721-4732.2005 · Cited by 1,152
Hit and lead generation: beyond high-throughput screening
Bleicher, K. H., Böhm, H.-J., Müller, K., & Alanine, A. I. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1086 · Cited by 1,056
Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect
Gao, M., Nettles, R. E., Belema, M., Snyder, L. B., Nguyen, V. N., Fridell, R. A., Serrano-Wu, M. H., Langley, D. R., Sun, J.-H., O’Boyle II, D. R., et al. (2010) · Nature · doi:10.1038/nature08960 · Cited by 939 · cited 1×
“This approach was used to discover compounds that inhibited hepatitis C virus replication and, after consequent optimization, the approach yielded efficacious clinical candidates with a broad genotype coverag”
MethodA Specific Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase
Fry, D. W., Kraker, A. J., McMichael, A., Ambroso, L. A., Nelson, J. M., Leopold, W. R., Connors, R. W., & Bridges, A. J. (1994) · Science · doi:10.1126/science.8066447 · Cited by 806
Research works printed but not linked: 5
- Landers, P. Human Element: drug industry's big push into technology falls short — testing machines were built to streamline research — but may be stifling it — officials see payoff after 2010. The Wall Street Journal 1 (24 Feb 2004).
- Mullin, R. As high-throughput screening draws fire, researchers leverage science to put automation into perspective. Chem. Eng. News 82, 23–32 (2004).
- HTStec Limited. Cellular Assay Reagents Trends 2009 Report (Cambridge, UK, 2009).
- LaMattina, J. L. (ed.) in Drug Truths: Dispelling the Myths About Pharma R&D 65–66 (John Wiley and Sons, Inc., Hoboken, New Jersey, 2009).
- Inglese, J. in Ask the Expert Forum, ACS Chemical Biology. ACS Publications [online] http://community.acs.org/ChemBiol/AsktheExpert/AsktheExpertArchive/tabid/67/Default.aspx (2008).
Cited by
Items 301–400 of 1,000
The Purchasable Chemical Space: A Detailed Picture
Lucas, X., Grüning, B. A., Bleher, S., & Günther, S. (2015) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.5b00116 · Cited by 46
Novel approaches to glioma drug design and drug screening
Patil, S. A., Hosni-Ahmed, A., Jones, T. S., Patil, R., Pfeffer, L. M., & Miller, D. D. (2013) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2013.807248 · Cited by 46
“Other types of HTS are also available and have been reviewed elsewhere [72-75].”
BackgroundKeck, T. M., Burzynski, C., Shi, L., & Newman, A. H. (2014) · Advances in pharmacology · doi:10.1016/b978-0-12-420118-7.00007-x · Cited by 49
“The advancement of high-throughput screens (Macarron et al., 2011) and rational lead design and optimization with in silico models (Jorgensen, 2009) have been a more recent source of novel leads.”
5.14 Biofabrication in Tissue Engineering ☆
Woodfield, T. B. F., Lim, K. S., Morouço, P., Levato, R., Malda, J., & Melchels, F. P. W. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-803581-8.10221-8 · Cited by 51
Early Probe and Drug Discovery in Academia: A Minireview
Roy, A. (2018) · Microarrays · doi:10.3390/ht7010004 · Cited by 49
“High-throughput screening (HTS) is an essential enabling technology for translational research that can have endpoints of drug discovery or probe discovery [1].”
BackgroundForming a Large-Scale Droplet Array in a Microcage Array Chip for High-Throughput Screening
Xu, J., Huang, M., Wang, H., & Fang, Q. (2019) · Analytical Chemistry · doi:10.1021/acs.analchem.9b02288 · Cited by 46
High-Throughput Screening for Drug Discovery
(2022) · IntechOpen eBooks · doi:10.5772/intechopen.91075 · Cited by 45
Graph-based generative models for de Novo drug design
Xiao-lin, X., Hu, J., Wang, Y., Zhang, L., & Liu, Z. (2019) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2020.11.004 · Cited by 57
Ekins, S., Pottorf, R., Reynolds, R. C., Williams, A. J., Clark, A. M., & Freundlich, J. S. (2014) · Journal of Chemical Information and Modeling · doi:10.1021/ci500077v · Cited by 43
Fluorescence Probe for Lysophospholipase C/NPP6 Activity and a Potent NPP6 Inhibitor
Kawaguchi, M., Okabe, T., Okudaira, S., Hanaoka, K., Fujikawa, Y., Terai, T., Komatsu, T., Kojima, H., Aoki, J., & Nagano, T. (2011) · Journal of the American Chemical Society · doi:10.1021/ja201028t · Cited by 45
Oehler, S., Lucaroni, L., Migliorini, F., Elsayed, A., Prati, L., Puglioli, S., Matasci, M., Schira, K., Scheuermann, J., Yudin, D., et al. (2023) · Nature Chemistry · doi:10.1038/s41557-023-01257-3 · Cited by 44
“EFs were calculated dividing the normalized sequence counts of a given library member (AxBy combination) with the average sequence count of the respective selection experiment (Supplementary Tables 2 and 3).”
BackgroundWang, J., Guo, Z., Fu, Y., Wu, Z., Huang, C., Zheng, C., Shar, P. A., Wang, Z., Xiao, W., & Wang, Y. (2016) · Briefings in Bioinformatics · doi:10.1093/bib/bbw018 · Cited by 49
Maximising success in multidrug formulation development: A review
Kavanagh, O. N., Albadarin, A. B., Croker, D. M., Healy, A. M., & Walker, G. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.05.024 · Cited by 45
King, T. A., Stewart, H. L., Mortensen, K. T., North, A. J. P., Sore, H. F., & Spring, D. R. (2019) · European Journal of Organic Chemistry · doi:10.1002/ejoc.201900847 · Cited by 44
Repin, M., Pampou, S., Karan, C., Brenner, D. J., & Garty, G. Y. (2017) · Radiation Research · doi:10.1667/rr011cc.1 · Cited by 43
“In comparison to manual processing, HTS systems provide higher throughput and, importantly, reduced variations leading to better quality data (18).”
BackgroundSatyanarayanajois, S. D., & Hill, R. A. (2011) · Future Medicinal Chemistry · doi:10.4155/fmc.11.135 · Cited by 49
Chen, Q., He, Z., Liu, W., Lin, X., Wu, J., Li, H., & Lin, J. (2015) · Advanced Healthcare Materials · doi:10.1002/adhm.201500383 · Cited by 44
Molecular Imaging in Drug Discovery and Development
Lindner, J. R., & Link, J. (2018) · Circulation Cardiovascular Imaging · doi:10.1161/circimaging.117.005355 · Cited by 47
“In particular, drug discovery has been accelerated by the maturation of high-throughput technologies for rapid and automated candidate molecule screening, the pharmaceutical application of omics approaches to understand the basis of health and disease-related targets, and the use of virtual screens for understanding s…”
BackgroundValeur, E., & Jimonet, P. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00378 · Cited by 43
Target-Directed Approaches for Screening Small Molecules against RNA Targets
Haniff, H. S., Knerr, L., Chen, J. L., Disney, M. D., & Lightfoot, H. L. (2020) · SLAS DISCOVERY · doi:10.1177/2472555220922802 · Cited by 44
“An alternative strategy, fragment-based drug discovery (FBDD), consists of screening smaller sets of fragments for chemical starting points.(143) Fragments, defined as having less than 20 nonhydrogen atoms, allow for more efficient sampling of the chemical space than drug-like molecules.”
BackgroundInfluentialHarnessing Reversed Allosteric Communication: A Novel Strategy for Allosteric Drug Discovery
Fan, J., Liu, Y., Kong, R., Ni, D., Yu, Z., Lu, S., & Zhang, J. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01695 · Cited by 48
Discovery of 1,8-acridinedione derivatives as novel GCN5 inhibitors via high throughput screening
Xiong, H., Han, J., Wang, J., Lu, W., Wang, C., Chen, Y., Lian, F., Zhang, N., Liu, J. Y.-C., Zhang, C., et al. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.02.005 · Cited by 43
Kumar, V., Lakshman, P. K. C., Prasad, T. K., Manjunath, K., Bairy, S. G., Vasu, A. S., Ganavi, B., Jasti, S., & Kamariah, N. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e23864 · Cited by 50
Bakken, G. A., Bell, A., Boehm, M., Everett, J. R., Gonzales, R., Hepworth, D., Klug-McLeod, J. L., Lanfear, J., Loesel, J., Mathias, J. P., et al. (2012) · Journal of Chemical Information and Modeling · doi:10.1021/ci300372a · Cited by 42
Leveridge, M. V., Buxton, R., Argyrou, A., Francis, P. L., Leavens, B. J., West, A., Rees, M., Hardwicke, P., Bridges, A. M., Ratcliffe, S. J., et al. (2013) · SLAS DISCOVERY · doi:10.1177/1087057113496276 · Cited by 42
“Some argue that HTS has dramatically reduced the cost and time taken to find molecules(1) and that screening collections of millions of diverse compounds is a successful method for identifying leads for more than 60% of targets.(2) Others believe that HTS is a “brute-force” approach and moves away from classic and mor…”
MethodProtein–Protein Interaction Inhibition (2P2I)-Oriented Chemical Library Accelerates Hit Discovery
Milhas, S., Raux, B., Betzi, S., Derviaux, C., Roche, P., Restouin, A., Basse, M.-J., Rebuffet, E., Lugari, A., Badol, M., et al. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.6b00286 · Cited by 44
Reaction screening in continuous flow reactors
Mohamed, D. K. B., Yu, X., Li, J., & Wu, J. (2016) · Tetrahedron Letters · doi:10.1016/j.tetlet.2016.07.072 · Cited by 42
Hammoud, M. K., Yosef, H. K., Lechtonen, T., Aljakouch, K., Schuler, M., Alsaidi, W., Daho, I., Maghnouj, A., Hahn, S. A., El‐Mashtoly, S. F., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-33682-7 · Cited by 43
Faster, better, and cheaper: harnessing microfluidics and mass spectrometry for biotechnology
Ha, N. S., de Raad, M., Han, L. Z., Golini, A. N., Petzold, C. J., & Northen, T. R. (2021) · RSC Chemical Biology · doi:10.1039/d1cb00112d · Cited by 45
Recent advances in small molecule inhibitors of deubiquitinating enzymes
Liu, P., Chen, Z., Guo, Y., He, Q., & Pan, C. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117324 · Cited by 46
Ekins, S., Freundlich, J. S., & Reynolds, R. C. (2014) · Journal of Chemical Information and Modeling · doi:10.1021/ci500264r · Cited by 40
The small molecule drug discovery process – from target selection to candidate selection
Stocks, M. J. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-397176-0.00003-0 · Cited by 41
Idea2Data: Toward a New Paradigm for Drug Discovery
Nicolaou, C. A., Humblet, C. C., Hu, H., Domínguez-Martín, E. M., Dorsey, F. C., Castle, T. M., Burton, K. I., Hu, H., Hendle, J., Hickey, M. J., et al. (2019) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.8b00488 · Cited by 41
Ligand- and Structure-Based Virtual Screening in Drug Discovery
Bhunia, S. S., Saxena, M., & Saxena, A. K. (2021) · Topics in medicinal chemistry · doi:10.1007/7355_2021_130 · Cited by 51
Wolfe, M. T., & Shepherd, D. A. (2013) · Entrepreneurship Theory and Practice · doi:10.1111/etap.12080 · Cited by 49
“…& Woodhead, 2009; Whittaker, Law, Ichihara, Hesterkamp, & Hallett, 2010) (a fact that we will discuss in detail later), in this study, we focus on the process of high-throughput screening (HTS), a technique that has historically been a cornerstone of pharmaceutical research (Macarron et al., 2011).”
BackgroundGielen, F., Buryska, T., Vliet, L. V., Butz, M., Damborsky, J., Prokop, Z., & Hollfelder, F. (2015) · Analytical Chemistry · doi:10.1021/ac503336g · Cited by 40
Protein-Directed Dynamic Combinatorial Chemistry: A Guide to Protein Ligand and Inhibitor Discovery
Huang, R., & Leung, I. K. H. (2016) · Molecules · doi:10.3390/molecules21070910 · Cited by 40
“Whilst HTS has proven to be an invaluable tool in inhibitor and drug discovery, it can be expensive, time consuming and—depending on the composition of the screening library—the screen may only cover a limited chemical space, thus potentially limiting the number of unique chemical scaffolds that can be identified from…”
BackgroundMeanwell, N. A. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00915 · Cited by 42
Gautam, V., Gaurav, A., Masand, N., Lee, V. S., & Patil, V. M. (2022) · Molecular Diversity · doi:10.1007/s11030-022-10489-3 · Cited by 44
“The concentration–response data for compound libraries obtained from HTS keep growing with every passing day making it one of the major contributors to the current big data environment in drug discovery [30, 31].”
BackgroundTrends in Protein-Based Biosensor Assemblies for Drug Screening and Pharmaceutical Kinetic Studies
Gonçalves, A. M., Pedro, A. Q., Santos, F. M., Martins, L. C., Maia, C. J., Queiroz, J. A., & Passarinha, L. A. (2014) · Molecules · doi:10.3390/molecules190812461 · Cited by 40
“Over the past two decades, several screening methodology approaches were used, including fragment screening [3], structure-based design [4], virtual screening [5] and high-throughput screening (HTS) [2].”
BackgroundMethodZhou, H., Cao, H., & Skolnick, J. (2018) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.8b00309 · Cited by 39
Machine Learning Assisted Hit Prioritization for High Throughput Screening in Drug Discovery
Boldini, D., Friedrich, L., Kühn, D., & Sieber, S. A. (2024) · ACS Central Science · doi:10.1021/acscentsci.3c01517 · Cited by 59
Artificial Intelligence (AI) in Pharmaceutical Formulation and Dosage Calculations
Joshi, S., & Sheth, S. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17111440 · Cited by 42
“For example, as demonstrated by Macarron et al. (2011), high-throughput, AI-enabled screening not only accelerates lead compound identification but also informs preformulating studies by predicting solubility, stability, and excipient compatibility, which are critical determinants in developing…”
InfluentialNanostructured sensors for biomedical applications — a current perspective
Krishnamoorthy, S. (2015) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2014.11.019 · Cited by 44
Bithi, S. S., Wang, W. S., Sun, M. Z., Bławzdziewicz, J., & Vanapalli, S. A. (2014) · Biomicrofluidics · doi:10.1063/1.4885079 · Cited by 39
Guiding Principles for Natural Product Drug Discovery
Camp, D., Davis, R. A., Evans‐Illidge, E., & Quinn, R. J. (2012) · Future Medicinal Chemistry · doi:10.4155/fmc.12.55 · Cited by 44
Virtual Screening Meets Deep Learning
Pérez-Sianes, J., Pérez‐Sánchez, H., & Díaz, F. (2018) · Current Computer - Aided Drug Design · doi:10.2174/1573409914666181018141602 · Cited by 40
High-throughput screening of nanoparticles in drug delivery
Tomé, I., Francisco, V., Fernandes, H., & Ferreira, L. (2021) · APL Bioengineering · doi:10.1063/5.0057204 · Cited by 41
The fall and rise of pharmacology – (Re-)defining the discipline?
Winquist, R. J., Mullane, K., & Williams, M. J. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.09.011 · Cited by 44
“The practical utility of such screens, especially in the area of drug discovery, became debatable as the data output easily overwhelmed the ability to productively analyze it such that HTS became widely viewed as ‘‘anti-intellectual and irrational’’ [223].”
BackgroundThe evolution of drug discovery: from phenotypes to targets, and back
Al‐Ali, H. (2016) · MedChemComm · doi:10.1039/c6md00129g · Cited by 46
Design and sustainability of polypeptide material systems
Yorke, S. K., Yang, Z., Wiita, E. G., Kamada, A., Knowles, T. P. J., & Buehler, M. J. (2025) · Nature Reviews Materials · doi:10.1038/s41578-025-00793-3 · Cited by 44
“The exhaustive solution is performing brute-force search across the whole design space for target proteins using techniques such as high-throughput screening 198,199 .”
Four disruptive strategies for removing drug discovery bottlenecks
Ekins, S., Waller, C. L., Bradley, M. P., Clark, A. M., & Williams, A. J. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.10.007 · Cited by 38
Increasing the delivery of next generation therapeutics from high throughput screening libraries
Wigglesworth, M. J., Murray, D. C., Blackett, C., Kossenjans, M., & Nissink, J. W. M. (2015) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2015.04.006 · Cited by 38
In Silico HTS and Structure Based Optimization of Indazole-Derived ULK1 Inhibitors
Wood, S. D., Grant, W. M., Adrados, I., Choi, J. Y., Alburger, J. M., Duckett, D. R., & Roush, W. R. (2017) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.7b00344 · Cited by 38
Application of Bioactivity Profile-Based Fingerprints for Building Machine Learning Models
Sturm, N., Sun, J., Vandriessche, Y., Mayr, A., Klambauer, G., Carlsson, L., Engkvist, O., & Chen, H. (2018) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.8b00550 · Cited by 41
“…advent of high-throughput screening (HTS) technologies in the early 90s, where typically millions of compounds can be screened within a few weeks, 10 the large amount of accumulated biochemical and cell-based HTS data in pharmaceutical industry became a valuable source for building the so called…”
BackgroundLimonin as a Starting Point for the Construction of Compounds with High Scaffold Diversity
Furiassi, L., Tonogai, E. J., & Hergenrother, P. J. (2021) · Angewandte Chemie International Edition · doi:10.1002/anie.202104228 · Cited by 38
Saha, P., Panda, D., & Dash, J. (2023) · Chemical Society Reviews · doi:10.1039/d3cs00166k · Cited by 42
A Turing Test for Molecular Generators
Bush, J. T., Pogány, P., Pickett, S. D., Barker, M., Baxter, A., Campos, S., Cooper, A. W. J., Hirst, D. J., Inglis, G. G. A., Nadin, A. J., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01148 · Cited by 41
Self-citationEvolving biomaterials design from trial and error to intelligent innovation
Hang, R., Yao, X., Bai, L., & Hang, R. (2025) · Acta Biomaterialia · doi:10.1016/j.actbio.2025.03.013 · Cited by 40
Bueno, J. (2016) · Journal of Microbial & Biochemical Technology · doi:10.4172/1948-5948.1000281 · Cited by 39
“Natural products for antibacterial drug screening has had a significant decrease in the obtainment of new leads, since the advent of high throughput screening methods, and the increase in its replacement of screening of chemical libraries from combinatorial chemistry [96].”
BackgroundDesigning DNA Encoded Libraries of Diverse Products in a Focused Property Space
Zhu, H., Flanagan, M. E., & Stanton, R. V. (2019) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.9b00729 · Cited by 37
Jaman, Z., Logsdon, D. L., Szilágyi, B., Sobreira, T. J. P., Aremu, D., Avramova, L. V., Cooks, R. G., & Thompson, D. H. (2020) · ACS Combinatorial Science · doi:10.1021/acscombsci.9b00212 · Cited by 37
Chemical biology and medicinal chemistry of RNA methyltransferases
Fischer, T. R., Meidner, J. L., Schwickert, M., Weber, M., Zimmermann, R. A., Kersten, C., Schirmeister, T., & Helm, M. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkac224 · Cited by 37
“In high-throughput screening (HTS) campaigns up to millions of compounds can be tested to find new hits, provided a robust and sensitive assay format is available (167).”
BackgroundIdentification of a novel ATM inhibitor with cancer cell specific radiosensitization activity
Dohmen, A. J. C., Qiao, X., Duursma, A. M., Wijdeven, R. H. M., Lieftink, C., Hageman, F., Morris, B., Halonen, P., Vens, C., van den Brekel, M. W. M., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.18034 · Cited by 40
“Compound screening allows for identification of compounds with a certain biological effect without the need for prior knowledge of the mechanism or the target, which facilitates the identification of critical targets [15].”
Liu, Y., Cao, Q., Yong, S., Wang, J., Chen, X., Yumei, X., Lin, J., Yang, M., Wang, K., Li, X., et al. (2025) · Biomaterials · doi:10.1016/j.biomaterials.2025.123348 · Cited by 36
TB Mobile: a mobile app for anti-tuberculosis molecules with known targets
Ekins, S., Clark, A. M., & Sarker, M. (2013) · Journal of Cheminformatics · doi:10.1186/1758-2946-5-13 · Cited by 33
“In recent years there has been an increase in the efforts around high throughput screening (HTS) for Mtb, in order to find compounds as therapeutics against TB [8-12] at a cost of millions of dollars, with resultant low single-digit (or less) hit rates [8,9,13,14].”
Backgroundde Rond, T., Gao, J., Zargar, A., de Raad, M., Cunha, J., Northen, T. R., & Keasling, J. D. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201901782 · Cited by 36
Wang, B., Wang, L., Gu, S., Yu, Y., Huang, H., Mo, K., Xu, H., Zeng, F., Xiao, Y., Peng, L., et al. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0122-1 · Cited by 38
“Cell-based “phenotypic” high-throughput screening (HTS) is a powerful unbiased tool to identify gene targets or small-molecule compounds exerting the desired effect.(12) In a disease-associated HTS study, thousands of chemicals can be screened and analyzed in a short time period with viable repeatability.”
BackgroundZhou, M., Li, W., Li, J., Xie, L., Wu, R., Wang, L., Fu, S., Su, W., Hu, J., Wang, J., et al. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra120.012981 · Cited by 37
“High-throughput screening provides a powerful strategy for the discovery of drugs that modulate various biomolecular interactions (6).”
BackgroundNanodelivery of STING agonists against cancer and infectious diseases
Zhou, J., Ventura, C. J., Fang, R. H., & Zhang, L. (2021) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2021.101007 · Cited by 37
Privileged heterocycles for DNA-encoded library design and hit-to-lead optimization
Wen, X., Wu, X., Jin, R., & Lu, X. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.115079 · Cited by 39
Human Disease and Drug Pharmacology, Complex as Real Life
Viayna, E., Sola, I., Pietro, O. D., & Muñoz‐Torrero, D. (2013) · Current Medicinal Chemistry · doi:10.2174/0929867311320130002 · Cited by 39
“interactions [2] as well as the assumption that a particular disease is caused by an abnormality in one disease-causing gene and in the protein it encodes, has prompted a”
BackgroundMF-PCBA: Multifidelity High-Throughput Screening Benchmarks for Drug Discovery and Machine Learning
Buterez, D., Janet, J. P., Kiddle, S. J., & Lió, P. (2023) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.2c01569 · Cited by 46
Unraveling Nature’s Pharmacy: Transforming Medicinal Plants into Modern Therapeutic Agents
Vaou, N., Voidarou, C. C., Rozos, G., Saldari, C., Stavropoulou, E., Vrioni, G., & Tsakris, A. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17060754 · Cited by 35
Clark, A. M., Sarker, M., & Ekins, S. (2014) · Journal of Cheminformatics · doi:10.1186/s13321-014-0038-2 · Cited by 33
“Unfortunately the hit rates of this approach are usually low single-digit (or less) [1,16,19,20] which makes this a very costly and wasteful exercise.”
BackgroundFlagstad, T., Min, G. K., Bonnet, K., Morgentin, R., Roche, D., Clausen, M. H., & Nielsen, T. E. (2016) · Organic & Biomolecular Chemistry · doi:10.1039/c6ob00961a · Cited by 35
Gubler, H., Clare, N., Galafassi, L., Geissler, U., Girod, M., & Herr, G. (2018) · SLAS DISCOVERY · doi:10.1177/2472555217752140 · Cited by 38
Mswahili, M. E., Martin, G. L., Woo, J., Choi, G. J., & Jeong, Y.-S. (2021) · Biomolecules · doi:10.3390/biom11121750 · Cited by 36
Behnen, J., Köster, H., Neudert, G., Craan, T., Heine, A., & Klebe, G. (2011) · ChemMedChem · doi:10.1002/cmdc.201100490 · Cited by 39
Machine learning and docking models for Mycobacterium tuberculosis topoisomerase I
Ekins, S., Godbole, A. A., Kéri, G., Őrfi, L., Pató, J., Bhat, R. S., Verma, R., Bradley, E. K., & Nagaraja, V. (2017) · Tuberculosis · doi:10.1016/j.tube.2017.01.005 · Cited by 40
Engineering, on‐demand manufacturing, and scaling‐up of polymeric nanocapsules
Crecente‐Campo, J., & Alonso, M. J. (2018) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10118 · Cited by 35
Pandya, A., Howard, M. J., Zloh, M., & Dalby, P. A. (2018) · Pharmaceutics · doi:10.3390/pharmaceutics10040165 · Cited by 37
Femina, T. A., Barghavi, V., Archana, K., Swethaa, N. G., & Ravi, M. (2022) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2022.107238 · Cited by 39
BayBE: a Bayesian Back End for experimental planning in the low-to-no-data regime
Fitzner, M., Šošić, A., Hopp, A. V., Müller, M., Rihana, R., Hrovatin, K., Liebig, F., Winkel, M., Halter, W., & Brandenburg, J. G. (2025) · Digital Discovery · doi:10.1039/d5dd00050e · Cited by 44
Advancing Organic Chemistry Using High‐Throughput Experimentation
Nsouli, R., Galiyan, G., & Ackerman, L. K. G. (2025) · Angewandte Chemie International Edition · doi:10.1002/anie.202506588 · Cited by 37
Holenz, J., & Stoy, P. (2018) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2018.12.001 · Cited by 35
Oehler, S., Catalano, M., Scapozza, I., Bigatti, M., Bassi, G., Favalli, N., Mortensen, M. R., Samain, F., Scheuermann, J., & Neri, D. (2021) · Chemistry - A European Journal · doi:10.1002/chem.202100816 · Cited by 34
Yuel: Improving the Generalizability of Structure-Free Compound–Protein Interaction Prediction
Wang, J., & Dokholyan, N. V. (2022) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.1c01531 · Cited by 38
Tamura, R., Tsuda, K., & Matsuda, S. (2023) · Science and Technology of Advanced Materials Methods · doi:10.1080/27660400.2023.2232297 · Cited by 44
“Robotic experiments have progressed to realize laboratory automation of chemical analysis and high-throughput screening in the field of biology [23–26].”
MethodRecent advances in ligand-enabled palladium-catalyzed divergent synthesis
Wang, Y., Feng, J., Li, E., Jia, Z., & Loh, T. (2023) · Organic & Biomolecular Chemistry · doi:10.1039/d3ob01679j · Cited by 34
Paricharak, S., Méndez‐Lucio, O., Ravindranath, A. C., Bender, A., IJzerman, A. P., & van Westen, G. J. P. (2016) · Briefings in Bioinformatics · doi:10.1093/bib/bbw105 · Cited by 39
Jaman, Z., Mufti, A., Sah, S., Avramova, L. V., & Thompson, D. H. (2018) · Chemistry - A European Journal · doi:10.1002/chem.201801165 · Cited by 34
The Melding of Drug Screening Platforms for Melanoma
Couto, G. K., Segatto, N. V., Oliveira, T. L., Seixas, F. K., Schachtschneider, K. M., & Collares, T. V. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00512 · Cited by 35
Shen, J., Zhang, G.-M., Zhang, Z., Zhang, L., Zhuang, Z., Qian, Y., Dou, Y., Wang, S., Wang, D. S., & Wang, Y. (2025) · Advanced Materials · doi:10.1002/adma.202416463 · Cited by 33
Microscale Symmetrical Electroporator Array as a Versatile Molecular Delivery System
Ouyang, M., Hill, W., Lee, J., & Hur, S. (2017) · Scientific Reports · doi:10.1038/srep44757 · Cited by 36
Identification of Compounds That Interfere with High‐Throughput Screening Assay Technologies
David, L., Walsh, J. J., Sturm, N., Feierberg, I., Nissink, J. W. M., Chen, H., Bajorath, J., & Engkvist, O. (2019) · ChemMedChem · doi:10.1002/cmdc.201900395 · Cited by 36
Exploration of the Chemical Space of DNA‐encoded Libraries
Pikalyova, R., Zabolotna, Y., Volochnyuk, D. M., Horvath, D., Marcou, G., & Varnek, A. A. (2022) · Molecular Informatics · doi:10.1002/minf.202100289 · Cited by 33
Affinity purification in target identification: the specificity challenge
Zheng, W., Li, G., & Li, X. (2015) · Archives of Pharmacal Research · doi:10.1007/s12272-015-0635-2 · Cited by 34
“Target-based rational design and screening of compound libraries against known targets are employed to discover candidate compounds for further drug development (Bajorath 2002; Posner 2005; Inglese et al. 2007; Macarron et al. 2011).”
BackgroundOpen innovation in early drug discovery: roadmaps and roadblocks
Reichman, M., & Simpson, P. B. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.12.008 · Cited by 34
Comparative pharmacokinetic profile of cyclosporine (CsA) with a decapeptide and a linear analogue
Price, D. A., Eng, H. F., Farley, K. A., Goetz, G. H., Huang, Y., Jiao, Z., Kalgutkar, A. S. S., Kablaoui, N. M., Khunte, B., Liras, S. I., et al. (2017) · Organic & Biomolecular Chemistry · doi:10.1039/c7ob00096k · Cited by 33
Metadata
- Authors
- Macarron, R., Banks, M. N., Bojanic, D., Burns, D. J., Cirovic, D. A., Garyantes, T., Green, D. V. S., Hertzberg, R. P., Janzen, W. P., Paslay, J. W., Schopfer, U., & Sittampalam, G. S.
- Affiliations
- Bristol-Myers Squibb (United States) (US)
- Novartis (United States) (US)
- Abbott (United States) (US)
- Sanofi (France) (FR)
- GlaxoSmithKline (United Kingdom) (GB)
- GlaxoSmithKline (United States) (US)
- University of North Carolina at Chapel Hill (US)
- The University of Kansas Cancer Center (US)
- Novartis (Switzerland) (CH)
- Pfizer (United States) (US)
- Venue
- Nature Reviews Drug Discovery
- Published
- 2011-03
- Volume
- 10
- Issue
- 3
- Pages
- 188-195
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2031441006
- Cited by
- 1,364
- References
- 65
- Citations by year
- 2026: 113 · 2025: 117 · 2024: 99 · 2023: 103 · 2022: 82 · 2021: 107 · 2020: 106 · 2019: 77 · 2018: 105 · 2017: 87 · 2016: 96 · 2015: 64 · 2014: 61 · 2013: 73 · 2012: 54
- FWCI
- 6.80
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Keywords
- high-throughput screening, drug discovery, chemical biology
- MeSH terms
- Animals, Drug Evaluation, Preclinical, Humans, Drug Design, Biomedical Research, Small Molecule Libraries
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.